Search

Your search keyword '"L, Einhorn"' showing total 10 results
Start Over Author "L, Einhorn" Journal cancer treatment reports
10 results on '"L, Einhorn"'

1. Cisplatin, vinblastine, and bleomycin in the treatment of metastatic melanoma: a phase II study of the Southeastern Cancer Study Group

Author

D H, Johnson, C, Presant, L, Einhorn, A A, Bartolucci, and F A, Greco

Subjects
Adult, Male, Leukopenia, Middle Aged, Vinblastine, Thrombocytopenia, Bleomycin, Antineoplastic Combined Chemotherapy Protocols, Drug Evaluation, Humans, Female, Cisplatin, Melanoma, Aged
Abstract

Fifty-one patients with metastatic melanoma were treated with cisplatin, vinblastine, and bleomycin. Of the 50 evaluable patients, 11 (22%) achieved an objective response, including three complete (6%) and eight partial (16%) responses. Four of the 11 responding patients had previously received dacarbazine; the remaining patients had received no prior chemotherapy. Responses were noted in cutaneous and lymph node sites as well as visceral metastases. However, with one exception, all responding patients with visceral involvement had lung metastases. Response durations were brief and toxicity was substantial. Nadir leukocyte counts less than 0.5 X 10(9)/L occurred in 28% of the patients. Debilitating neurotoxicity, primarily paralytic ileus, and severe nausea and emesis were experienced by 24% of the patients. The combination of cisplatin, vinblastine, and bleomycin is not sufficiently beneficial to warrant its use in metastatic melanoma.

Published
1985

8. Cisplatin, vinblastine, and bleomycin in the treatment of metastatic melanoma: a phase II study of the Southeastern Cancer Study Group.

Author

Johnson DH, Presant C, Einhorn L, Bartolucci AA, and Greco FA

Subjects
Adult, Aged, Antineoplastic Combined Chemotherapy Protocols adverse effects, Bleomycin administration & dosage, Bleomycin adverse effects, Cisplatin administration & dosage, Cisplatin adverse effects, Drug Evaluation, Female, Humans, Leukopenia chemically induced, Male, Melanoma secondary, Middle Aged, Thrombocytopenia chemically induced, Vinblastine administration & dosage, Vinblastine adverse effects, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Melanoma drug therapy
Abstract

Fifty-one patients with metastatic melanoma were treated with cisplatin, vinblastine, and bleomycin. Of the 50 evaluable patients, 11 (22%) achieved an objective response, including three complete (6%) and eight partial (16%) responses. Four of the 11 responding patients had previously received dacarbazine; the remaining patients had received no prior chemotherapy. Responses were noted in cutaneous and lymph node sites as well as visceral metastases. However, with one exception, all responding patients with visceral involvement had lung metastases. Response durations were brief and toxicity was substantial. Nadir leukocyte counts less than 0.5 X 10(9)/L occurred in 28% of the patients. Debilitating neurotoxicity, primarily paralytic ileus, and severe nausea and emesis were experienced by 24% of the patients. The combination of cisplatin, vinblastine, and bleomycin is not sufficiently beneficial to warrant its use in metastatic melanoma.

Published
1985

9. Chemotherapy for stage III-IV epithelial ovarian cancer with cis-dichlorodiammineplatinum(II), adriamycin, and cyclophosphamide: a preliminary report.

Author

Ehrlich CE, Einhorn L, Williams SD, and Morgan J

Subjects
Bone Marrow drug effects, Cisplatin adverse effects, Clinical Trials as Topic, Cyclophosphamide adverse effects, Doxorubicin adverse effects, Drug Administration Schedule, Drug Evaluation, Drug Therapy, Combination, Female, Heart Failure chemically induced, Humans, Kidney drug effects, Cisplatin administration & dosage, Cyclophosphamide administration & dosage, Doxorubicin administration & dosage, Ovarian Neoplasms drug therapy
Published
1979

Catalog

Books, media, physical & digital resources
See catalog results